Global Acute Myeloid Leukemia Therapeutics 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR112403227

Publication Date:

November 28, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Acute Myeloid Leukemia Therapeutics market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The report includes an overview of the development of the Acute Myeloid Leukemia Therapeutics industry chain, the market status of Hospitals (Pipeline Drugs, Chemotherapy Drugs), Clinics (Pipeline Drugs, Chemotherapy Drugs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Acute Myeloid Leukemia Therapeutics.
Regionally, the report analyzes the Acute Myeloid Leukemia Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Acute Myeloid Leukemia Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Acute Myeloid Leukemia Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Acute Myeloid Leukemia Therapeutics industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Pipeline Drugs, Chemotherapy Drugs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Acute Myeloid Leukemia Therapeutics market.
Regional Analysis: The report involves examining the Acute Myeloid Leukemia Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Acute Myeloid Leukemia Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Acute Myeloid Leukemia Therapeutics:
Company Analysis: Report covers individual Acute Myeloid Leukemia Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Acute Myeloid Leukemia Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Clinics).
Technology Analysis: Report covers specific technologies relevant to Acute Myeloid Leukemia Therapeutics. It assesses the current state, advancements, and potential future developments in Acute Myeloid Leukemia Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Acute Myeloid Leukemia Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Acute Myeloid Leukemia Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Pipeline Drugs
Chemotherapy Drugs
Chemotherapy Regimens
麻豆原创 segment by Application
Hospitals
Clinics
麻豆原创 Care
麻豆原创 segment by players, this report covers
Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals
Cephalon
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Acute Myeloid Leukemia Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Acute Myeloid Leukemia Therapeutics, with revenue, gross margin and global market share of Acute Myeloid Leukemia Therapeutics from 2019 to 2024.
Chapter 3, the Acute Myeloid Leukemia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Acute Myeloid Leukemia Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukemia Therapeutics.
Chapter 13, to describe Acute Myeloid Leukemia Therapeutics research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia Therapeutics
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Acute Myeloid Leukemia Therapeutics by Type
1.3.1 Overview: Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Acute Myeloid Leukemia Therapeutics Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Pipeline Drugs
1.3.4 Chemotherapy Drugs
1.3.5 Chemotherapy Regimens
1.4 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 麻豆原创 Care
1.5 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size & Forecast
1.6 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Ambit Biosciences Corporation
2.1.1 Ambit Biosciences Corporation Details
2.1.2 Ambit Biosciences Corporation Major Business
2.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Therapeutics Product and Solutions
2.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Ambit Biosciences Corporation Recent Developments and Future Plans
2.2 Genzyme Corporation Celgene Corporation
2.2.1 Genzyme Corporation Celgene Corporation Details
2.2.2 Genzyme Corporation Celgene Corporation Major Business
2.2.3 Genzyme Corporation Celgene Corporation Acute Myeloid Leukemia Therapeutics Product and Solutions
2.2.4 Genzyme Corporation Celgene Corporation Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Genzyme Corporation Celgene Corporation Recent Developments and Future Plans
2.3 Clavis Pharma ASA
2.3.1 Clavis Pharma ASA Details
2.3.2 Clavis Pharma ASA Major Business
2.3.3 Clavis Pharma ASA Acute Myeloid Leukemia Therapeutics Product and Solutions
2.3.4 Clavis Pharma ASA Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Clavis Pharma ASA Recent Developments and Future Plans
2.4 Sunesis Pharmaceuticals
2.4.1 Sunesis Pharmaceuticals Details
2.4.2 Sunesis Pharmaceuticals Major Business
2.4.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Therapeutics Product and Solutions
2.4.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Sunesis Pharmaceuticals Recent Developments and Future Plans
2.5 Cephalon
2.5.1 Cephalon Details
2.5.2 Cephalon Major Business
2.5.3 Cephalon Acute Myeloid Leukemia Therapeutics Product and Solutions
2.5.4 Cephalon Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Cephalon Recent Developments and Future Plans
2.6 Bristol-Myers Squibb
2.6.1 Bristol-Myers Squibb Details
2.6.2 Bristol-Myers Squibb Major Business
2.6.3 Bristol-Myers Squibb Acute Myeloid Leukemia Therapeutics Product and Solutions
2.6.4 Bristol-Myers Squibb Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.7 Novartis International AG
2.7.1 Novartis International AG Details
2.7.2 Novartis International AG Major Business
2.7.3 Novartis International AG Acute Myeloid Leukemia Therapeutics Product and Solutions
2.7.4 Novartis International AG Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Novartis International AG Recent Developments and Future Plans
2.8 GlaxoSmithKline
2.8.1 GlaxoSmithKline Details
2.8.2 GlaxoSmithKline Major Business
2.8.3 GlaxoSmithKline Acute Myeloid Leukemia Therapeutics Product and Solutions
2.8.4 GlaxoSmithKline Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 GlaxoSmithKline Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Acute Myeloid Leukemia Therapeutics Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Acute Myeloid Leukemia Therapeutics by Company Revenue
3.2.2 Top 3 Acute Myeloid Leukemia Therapeutics Players 麻豆原创 Share in 2023
3.2.3 Top 6 Acute Myeloid Leukemia Therapeutics Players 麻豆原创 Share in 2023
3.3 Acute Myeloid Leukemia Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Acute Myeloid Leukemia Therapeutics 麻豆原创: Region Footprint
3.3.2 Acute Myeloid Leukemia Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Acute Myeloid Leukemia Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Acute Myeloid Leukemia Therapeutics Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Acute Myeloid Leukemia Therapeutics Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Acute Myeloid Leukemia Therapeutics 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Acute Myeloid Leukemia Therapeutics Consumption Value by Type (2019-2030)
6.2 North America Acute Myeloid Leukemia Therapeutics Consumption Value by Application (2019-2030)
6.3 North America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country
6.3.1 North America Acute Myeloid Leukemia Therapeutics Consumption Value by Country (2019-2030)
6.3.2 United States Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Acute Myeloid Leukemia Therapeutics Consumption Value by Type (2019-2030)
7.2 Europe Acute Myeloid Leukemia Therapeutics Consumption Value by Application (2019-2030)
7.3 Europe Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Acute Myeloid Leukemia Therapeutics Consumption Value by Country (2019-2030)
7.3.2 Germany Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia Therapeutics Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Acute Myeloid Leukemia Therapeutics Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Acute Myeloid Leukemia Therapeutics Consumption Value by Region (2019-2030)
8.3.2 China Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Acute Myeloid Leukemia Therapeutics Consumption Value by Type (2019-2030)
9.2 South America Acute Myeloid Leukemia Therapeutics Consumption Value by Application (2019-2030)
9.3 South America Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country
9.3.1 South America Acute Myeloid Leukemia Therapeutics Consumption Value by Country (2019-2030)
9.3.2 Brazil Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia Therapeutics Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Acute Myeloid Leukemia Therapeutics Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Acute Myeloid Leukemia Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Acute Myeloid Leukemia Therapeutics Consumption Value by Country (2019-2030)
10.3.2 Turkey Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Acute Myeloid Leukemia Therapeutics 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Acute Myeloid Leukemia Therapeutics 麻豆原创 Drivers
11.2 Acute Myeloid Leukemia Therapeutics 麻豆原创 Restraints
11.3 Acute Myeloid Leukemia Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Acute Myeloid Leukemia Therapeutics Industry Chain
12.2 Acute Myeloid Leukemia Therapeutics Upstream Analysis
12.3 Acute Myeloid Leukemia Therapeutics Midstream Analysis
12.4 Acute Myeloid Leukemia Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals
Cephalon
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.